Teriparatide intranasal - Critical Pharmaceuticals

Drug Profile

Teriparatide intranasal - Critical Pharmaceuticals

Alternative Names: CP-046; CP046 PTH CriticalSorb

Latest Information Update: 24 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Critical Pharmaceuticals
  • Developer Critical Pharmaceuticals; University of Nottingham
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Osteoporosis

Most Recent Events

  • 15 Apr 2014 Phase-I clinical trials in Osteoporosis (in volunteers) in United Kingdom (Intranasal)
  • 21 Nov 2013 Preclinical trials in Osteoporosis in United Kingdom (Intranasal)
  • 21 Oct 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top